GlobalBlock Announces Application for Voluntary Management Cease Trade Order
London, United Kingdom and Vancouver, British Columbia–(Newsfile Corp. – April 20, 2023) – GlobalBlock Digital…
Month: April 2023
HKTDC unveils seven creative lifestyle, licensing events
HONG KONG, Apr 20, 2023 – (ACN Newswire) – The creative industry is a powerhouse…
Next Introduces ChatGPT Visibility and Adaptive Controls to Reveal Platform for Data Loss Prevention
Addressing Data Protection Challenges in the Age of Generative AI-Powered Language Models BOSTON & LONDON–(BUSINESS…
Digi International Announces 2023 Green Tech Customer Innovation Award Winners
Awards highlight customer initiatives and products that promote sustainability, environmental best practices, and carbon reduction…
Royal Gold Provides 2023 Guidance for GEO Sales, DD&A and Effective Tax Rate
DENVER–(BUSINESS WIRE)–Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold” or the “Company,”…
Center for Financial Professionals Names Experian to 2023 Global Fintech Leaders Report for Fourth Consecutive Year
Experian’s fraud prevention, advanced data and analytics, customer experience and credit decisioning remain key drivers…
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
The settlement between Statera Biopharma, Inc. and Biostax Corp. includes an amended royalty-bearing license agreement…
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
The settlement between Statera Biopharma, Inc. and Biostax Corp. includes an amended royalty-bearing license agreement…
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT…
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT…
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
Live moderated webcast with members of the Novan management team and dermatological key opinion leader,…
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
Live moderated webcast with members of the Novan management team and dermatological key opinion leader,…
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, April 20, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”),…
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, April 20, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”),…
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia
– GFH009 showed strong anti-tumor effect and clinical and biological efficacy; PK profile supports anticipated once…
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia
– GFH009 showed strong anti-tumor effect and clinical and biological efficacy; PK profile supports anticipated once…
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
WARRINGTON, Pa., April 20, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
WARRINGTON, Pa., April 20, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…